Wells Fargo & Company Issues Positive Forecast for Medline (NASDAQ:MDLN) Stock Price

Medline (NASDAQ:MDLN) had its price objective hoisted by Wells Fargo & Company from $42.00 to $47.00 in a research report report published on Friday morning,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other equities research analysts also recently commented on MDLN. TD Cowen started coverage on shares of Medline in a research report on Monday, January 12th. They issued a “buy” rating for the company. William Blair began coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating for the company. Piper Sandler began coverage on Medline in a research note on Monday, January 12th. They issued an “overweight” rating and a $50.00 price target on the stock. BMO Capital Markets increased their price objective on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Evercore restated an “outperform” rating and set a $55.00 target price on shares of Medline in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medline currently has an average rating of “Moderate Buy” and an average price target of $50.35.

Medline Price Performance

Shares of NASDAQ MDLN traded down $0.52 during mid-day trading on Friday, hitting $48.37. 844,446 shares of the company were exchanged, compared to its average volume of 3,304,363. The business’s 50 day moving average is $44.40. Medline has a 1-year low of $34.89 and a 1-year high of $50.88.

Medline (NASDAQ:MDLN) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The business had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The firm’s quarterly revenue was up 14.8% on a year-over-year basis.

Insider Buying and Selling at Medline

In related news, Director Andrew J. Mills purchased 2,586,206 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was bought at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the transaction, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles N. Mills purchased 2,579,310 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Hedge Funds Weigh In On Medline

Institutional investors have recently modified their holdings of the company. Carlyle Group Inc. acquired a new stake in Medline during the fourth quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new stake in shares of Medline during the fourth quarter worth $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline in the fourth quarter valued at $793,278,000. Morgan Stanley acquired a new position in Medline in the fourth quarter valued at $636,807,000. Finally, Capital Research Global Investors purchased a new position in Medline during the fourth quarter worth about $620,937,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple brokerages raised price targets and turned more constructive after the quarter — Citi raised its target to $60 (buy), UBS to $57 (buy), BMO to $54 (outperform) and RBC to $53 (outperform), signaling analyst confidence in Medline’s growth outlook. Analysts Boost Their Forecasts Following Q4 Results
• Positive Sentiment: Revenue beat: Q4 sales were $7.79B vs. consensus ~$7.52B, up ~14.8% year-over-year — supports top-line momentum and was called “record sales” in earnings highlights. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: The full Q4 earnings call transcript and company commentary are available for detail on margins, margin drivers and capital/ESOP plans — useful for assessing whether the EPS miss is one-off or structural. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Independent coverage provides quick snapshots of results and context on product/segment performance — use these to cross-check management’s narrative. Q4 Earnings Snapshot
• Negative Sentiment: EPS miss: reported EPS was ($0.01) vs. consensus $0.24 — the earnings shortfall is the primary near-term negative catalyst and was cited as the reason for the share gap down. Shares Gap Down Following Weak Earnings
• Negative Sentiment: IPO/ESOP scrutiny: the company’s public filing and ESOP plans are under increased public scrutiny, raising questions about governance, dilution and guidance clarity as Medline transitions to the public market. IPO Opens Public Scrutiny On Growth Guidance And ESOP Plans
• Negative Sentiment: Coverage noting “shortcomings”: some write-ups highlight that, despite growth, the quarter revealed weaknesses (profitability/mix) that need addressing — a reminder that revenue strength hasn’t fully translated into EPS beat. Reports Growth Despite Earnings Shortcomings

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.